Clinical trials: CTCL
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG